Henry Schein and Avery Dennison Stocks Steady Following Resilient FY2024 Results

Key Facts

Amid a macroeconomic environment defined by persistent inflationary pressures, recent earnings from the industrial and medical sectors demonstrate a notable capacity to navigate fluctuating global demand. Henry Schein reported fiscal 2024 revenue of $12.0 billion, marking a 2.5% increase driven by consistent demand in dental and medical markets. Similarly, Avery Dennison’s results highlighted significant margin resilience, as the company successfully offset softer sales volumes in specific segments through disciplined cost management and strategic initiatives.

These results arrive as investors weigh the performance of mid-to-large cap firms against industry peers; per market data, packaging and labeling competitors have faced volume headwinds similar to Avery Dennison, yet the latter’s focus on RFID technology has bolstered its profitability profile. Compared to previous quarterly benchmarks, Henry Schein’s steady revenue growth underscores a defensive quality in healthcare spending, providing a level of stability for the stock despite broader economic uncertainty.

Looking ahead, market participants are shifting focus toward macroeconomic catalysts that could impact operational costs. Recent U.S. Budget Balance data from July 13, 2026, showed a deficit of $120 billion, narrower than the projected $135.8 billion. In the absence of current real-time pricing, the upcoming U.S. Consumer Price Index (CPI) release on July 14 remains a critical watchpoint; with the previous annual inflation rate at 3.5%, these figures will likely dictate the trajectory of production costs and consumer sentiment for the remainder of the year.